Skip to Main Content

++

  • Organ transplant recipients are chronically immunosuppressed and their T cell function is impaired.
  • Ensuing diseases are mostly infections and are similar to those occurring in other conditions associated with T cell impairment, such as AIDS.
  • In addition, organ transplant recipients are at great risk for developing nonmelanoma skin cancer and other cancers.
  • Bone marrow and stem cell graft recipients are candidates for graft-versus-host disease (GVHD).

++

   Image not available. Image not available.

++

++

  • Staphylococcus, Streptococcus, Salmonella, Listeria, Nocardia, Mycobacterium avium-intracellulare, M. tuberculosis, Legionella
  • Cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), molluscum contagiosum virus, human papilloma virus (HPV), Epstein-Barr virus (EBV)
  • Candida, Cryptococcus, Histoplasma, Coccidioides, Blastomyces, Dermatophytes (onychomycosis), Aspergillus

++

*Clinical manifestations are discussed in their respective sections.

++

Image not available.

++

   Image not available. Image not available.

++

  • Nonmelanoma skin cancer is the most common malignancy in adult solid organ transplant patients.
  • The majority are squamous cell carcinomas (SCC) (Section 11).
  • The risk of developing SCC increases exponentially with the length of immunosuppression.
  • The cumulative incidence is 80% after 20 years of immunosuppression in renal transplantation. SCC in posttransplant patients are aggressive.
  • HPV infection is implicated in the pathogenesis.
  • Other epithelial proliferative lesions are actinic keratoses, keratoacanthomas, porokeratosis, appendage tumors, and Merkel cell carcinomas (Section 11).
  • Children with organ transplants may also be at higher risk for the development of melanoma (Section 12).
  • Lymphoproliferative disorders are common in graft recipients and related to Epstein-Barr virus (EBV)-mediated proliferation of B cells and most are lymphomas of B cell origin. Cutaneous T cell lymphomas account for 30% of cutaneous lymphomas in transplant patients (Section 20).
  • Kaposi sarcoma occurs in immunosuppressed transplant recipients with an incidence of 0.5–5%. All cases are associated with Kaposi sarcoma–associated herpesvirus (KSHV) infection (Section 20).

++

*Clinical manifestations are discussed in their respective sections.

++ ++

ICD: 9:996.85 • ICD-10: T86.0   Image not available. Image not available.

++

  • GVHD is the totality of organ dysfunction caused by the action of histoincompatible, immunocompetent donor cells against the tissues of an immunocompetent host.
  • Graft-versus-host reaction (GVHR) is the expression of GVHD in a specific organ (e.g., cutaneous GVHR).
  • Acute cutaneous GVHR is the earliest and most frequent GVHR. Liver and GI tract GVHR are also common.
  • Acute cutaneous GVHR, usually occurring 10–30 days after bone marrow transplantation (BMT), is characterized by faint erythematous macules, often in perifollicular pattern progressing to confluent erythema, erythroderma, or toxic epidermal necrolysis (TEN).
  • Chronic cutaneous GVHR occurs > 60 days after allogeneic BMT and manifests as lichenoid and sclerodermoid changes.

++

Epidemiology

++

Incidence

++

Allogeneic BMT: 20–80% of successful engraftments. Autologous BMT: mild cutaneous GVHR occurs in 8%. ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.